COMMUNIQUÉS West-GlobeNewswire

Oculis Reports Q1 2026 Financial Results and Provides Company Update
11/05/2026
Pipeline Advancing as Planned, Leading with OCS-01 Key Milestone Completion of LPLV in Both DIAMOND Phase 3 Trials; Data Readout on Track for June 2026 Licaminlimab PREDICT-1 Trial in Active Site Recruitment Phase, [...]
Coherus Oncology Reports First Quarter 2026 Financial Results and Provides Business Update
11/05/2026
– LOQTORZI ® net revenue of $11.8 million in Q1 2026 – – Patient accrual complete for 1L HCC Phase 2 randomized clinical trial for anti-IL27 casdozokitug, timing for data readouts tracking to projections – – Tagmokitug [...]
Ceribell Reports First Quarter 2026 Financial Results
11/05/2026
SUNNYVALE, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological [...]
Kyntra Bio Reports First Quarter 2026 Financial Results and Provides Business Update
11/05/2026
Phase 2 monotherapy trial of FG-3246, a potential first-in-class antibody drug conjugate (ADC) targeting CD46, in metastatic castration-resistant prostate cancer (mCRPC) is progressing well with the interim analysis [...]
Aktis Oncology Reports Financial Results and Business Highlights for First Quarter 2026
11/05/2026
Announced two-trial clinical development strategy for AKY-2519 enabling evaluation in multiple patient segments Initiated Phase 1b clinical trial of AKY-2519 in metastatic castration-resistant prostate cancer (mCRPC); [...]
ArriVent BioPharma Reports First Quarter 2026 Financial Results
11/05/2026
Topline global pivotal Phase 3 data for firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC expected mid-2026 IND clearance of ARR-002, ArriVent’s dual-targeting MUC16/NaPi2b tetravalent ADC, advances into [...]
Aura Biosciences Reports First Quarter 2026 Financial Results and Business Highlights
11/05/2026
Phase 3 CoMpass trial advancing toward enrollment completion, supporting 2H 2027 topline data Natalie Holles appointed Chief Executive Officer and President and member of the Board of Directors Strengthened balance [...]
Eikon Therapeutics Reports First Quarter 2026 Financial Results and Provides Clinical Updates
11/05/2026
Maintained strong financial position with $596 million in cash, cash equivalents and marketable securities as of March 31, 2026 Continued execution across the oncology pipeline, with a strategic focus on three priority [...]
Health Catalyst Reports First Quarter 2026 Results
11/05/2026
SALT LAKE CITY, May 11, 2026 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. (“Health Catalyst,” Nasdaq: HCAT), a healthcare intelligence company designed to accelerate measurable improvement for health systems, today [...]
Amwell® to Participate in Upcoming Investor Conference
11/05/2026
BOSTON, May 11, 2026 (GLOBE NEWSWIRE) -- Amwell ® (NYSE: AMWL), a leading provider of a comprehensive SaaS-based software platform for technology-enabled healthcare, today announced that Mark Hirschhorn, CFO and COO, [...]
Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provide Business Update on Wednesday, May 20, 2026
11/05/2026
BASEL, Switzerland and LONDON and NEW YORK, May 11, 2026 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Wednesday, May 20, 2026, to [...]
Immunovant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026, and Provide Business Update on Wednesday, May 20, 2026
11/05/2026
DURHAM, N.C., May 11, 2026 (GLOBE NEWSWIRE) -- Immunovant (Nasdaq: IMVT ) today announced that it will report its financial results for the fourth quarter and fiscal year ended March 31, 2026, and provide a business [...]
Elicio Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Updates
11/05/2026
In the ongoing Phase 2 AMPLIFY-7P study evaluating ELI-002 7P in patients with pancreatic ductal adenocarcinoma (“PDAC”), the event-driven primary disease-free survival (“DFS”) analysis is anticipated mid-year 2026 The [...]
Sangamo Therapeutics Announces First Quarter 2026 Earnings Call
11/05/2026
RICHMOND, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (OTCQB Venture Market: SGMO), a genomic medicine company today announced that the company has scheduled the release of its first quarter 2026 [...]
Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results
11/05/2026
First participant dosed in FORTIFY, a Phase 1b indication expansion trial of PLN-101095 Oral presentation at AACR 2026 featured updated data from Phase 1 trial of PLN-101095 showing deepening of confirmed responses in [...]
Metagenomi Therapeutics Reports Business Updates and First Quarter 2026 Financial Results
11/05/2026
On track for regulatory submission of MGX-001 to advance global clinical program, including investigational new drug application (“IND”) in 4Q 2026 Publication in Nature Structural & Molecular Biology highlights [...]
Sana Biotechnology Reports First Quarter 2026 Financial Results and Business Updates
11/05/2026
Announced strategic collaboration with Mayo Clinic, focused on improving care in type 1 diabetes and accelerating development of SC451 Continued progress toward starting SC451 Phase 1 trial later this year, including [...]
Outset Medical to Present at RBC Global Healthcare Conference
11/05/2026
SAN JOSE, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to improve clinical outcomes in dialysis with less [...]
LENZ Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
11/05/2026
Q1 2026 total revenue of $1.9 million, including $1.7 million in VIZZ ® product sales Approximately 46,000 paid prescriptions filled and over 10,000 prescribing eye care professionals from launch through Q1 2026 [...]

Pages